This week I’ll talk about restructuring the portfolio by using option strategies for healthcare stocks where I expect rising volatility. This strategy has been successful several times recently: our 700%+ options gain with McKesson, the recent 53% gain on Texas Instruments options, the recent 22% gain on… Read More
Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine. He has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.
Analyst Articles
Sell shares of Diebold Nixdorf (NYSE: DBD) and Ambarella (NSDQ: AMBA). Keep Diebold February Options Straddle open.I am recommending the sale of Diebold Nixdorf (NYSE: DBD) shares ahead of Italy’s referendum due to the increased potential risk to companies doing business in the Eurozone if the “No” vote prevails. Read More
It is the best of times if you own Texas Instruments, but not-so-great if you own Diebold, which just became Diebold Nixdorf. And while the former is firing on all cylinders, the latter remains a question mark, albeit with a flicker of hope, which makes it worth holding onto for… Read More
It’s time to give thanks and take profits on the Texas Instruments January 70 call option. I recommended the the option along with the stock in the September issue of Breakthrough Tech Profits. And while the stock has done well- up nearly 11% as of the close on 11/22/16 –… Read More
Trumpcare is coming but its makeup, its directives, and its effects are a big unknown. Thus, at least in the early innings, the use of options as a trading vehicle to capitalize from the movement in stocks that will likely be affected by this new dynamic is sensible. In my… Read More
It’s time to sell this straddle. I recommended the trade as a hedge against the election which Wall Street has surprisingly handled fairly well. Because of the relatively low volatility in the market after the election and the slow and steady move to the upside, the large move required to… Read More
- November 17, 2016
-
Download Issue
“Trumpcare” will unlock a bag of goodies for the Big Five. Read More
Shares of Airgain (NSDQ: AIRG) have exploded to the upside after a much better than expected earnings report released last week. I am recommending taking profits on the position with a near 50% gain in the shares as of the open of trading on November 15. Shares were initially… Read More
Certain biotech stocks, such as Gilead are likely to respond to changes in the healthcare system brought about by Trumpcare. This trade has yet to develop fully, yet has an excellent chance to deliver a significant profit once the stock breaks up or down. Read More
Shares of Airgain (NSDQ: AIRG), a leading provider of embedded premium high-performance antennas for electronic devices, rallied after it reported well-above expected earnings for its quarter ending on September 30, 2016. The company reported $12.4 million in sales, an 87% improvement over the prior year while delivering 16 cents per… Read More